Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

ClinicalTrials.gov ID: NCT03316300

Public ClinicalTrials.gov record NCT03316300. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2

Study identification

NCT ID
NCT03316300
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Neurotech Pharmaceuticals
Industry
Enrollment
120 participants

Conditions and interventions

Interventions

  • NT-501 Combination Product
  • Sham Procedure Procedure

Combination Product · Procedure

Eligibility (public fields only)

Age range
21 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 23, 2017
Primary completion
Aug 30, 2022
Completion
Sep 22, 2022
Last update posted
Sep 23, 2024

2017 – 2022

United States locations

U.S. sites
16
U.S. states
12
U.S. cities
16
Facility City State ZIP Site status
Scripps Clinic Medical Group La Jolla California 92037
Jules Stein Eye Institute / David Geffen School of Medicine Los Angeles California 90095
Byers Eye Institute at Stanford University Palo Alto California 94303
Bay Area Retina Associates Walnut Creek California 94598
Retina Consultants of Southern Colorado, P.C. Colorado Springs Colorado 80909
Retina Associates of New Orleans Metairie Louisiana 70006
National Institute of Health, NIH Bethesda Maryland 20892
Cumberland Valley Retina Consultants Hagerstown Maryland 21740
Associated Retinal Consultants, P.C. Royal Oak Michigan 48073
Sierra Eye Associates Reno Nevada 89502
Retina Associates of Cleveland, Inc. Cleveland Ohio 44122
Tulsa Retina Consultants Tulsa Oklahoma 74114
Retina Northwest, PC Portland Oregon 97221
Southeastern Retina Associates, PC Knoxville Tennessee 37922
Texas Retina Associates Dallas Texas 75231
University of Utah John A. Moran Eye Center Salt Lake City Utah 84132

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03316300, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 23, 2024 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03316300 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →